Defactinib for Mesothelioma: 344-Patient COMMAND Trial and What FAK Inhibitors Mean in 2026

Defactinib (VS-6063), a focal adhesion kinase (FAK) inhibitor developed by Verastem Oncology, failed to improve progression-free survival in unselected mesothelioma patients in the Phase II COMMAND trial (HR 1.04, p=0.86). However, a pre-specified biomarker analysis revealed that merlin-low patients — approximately 40-50% of all mesothelioma cases — experienced a 44% reduction in disease progression risk (HR 0.56). This finding has reshaped the FAK inhibitor landscape, redirecting research toward biomarker-selected combination strategies that could benefit thousands of patients who have exhausted standard treatment options.

What Are the Key Facts About Defactinib and FAK Inhibitors for Mesothelioma?

What Is FAK and Why Is It a Target in Mesothelioma?

Focal adhesion kinase (FAK) is an intracellular enzyme that sits at the intersection of multiple cancer-promoting signaling pathways. In healthy cells, FAK regulates cell adhesion, migration, and survival in a tightly controlled manner. In mesothelioma, FAK is frequently overactivated, driving tumor cells to survive, proliferate, and resist apoptosis (programmed cell death).^[11]

The connection between FAK and mesothelioma is rooted in the NF2 tumor suppressor gene. NF2 encodes the protein merlin, which normally keeps FAK activity in check. When NF2 is deleted or mutated — an event occurring in 40-50% of mesothelioma tumors — merlin protein is lost, and FAK becomes constitutively activated. This creates a molecular dependency: merlin-deficient mesothelioma cells rely on hyperactive FAK signaling for survival, making them potentially vulnerable to FAK inhibition.^[12]

"The biology behind FAK inhibitors in mesothelioma is compelling. When merlin is lost, FAK becomes the engine driving tumor growth. Blocking that engine with a targeted drug like defactinib is sound molecular logic — the challenge has been identifying which patients have that specific vulnerability."

— David Foster, Executive Director of Client Services, Danziger & De Llano

Beyond direct tumor cell effects, FAK also plays a critical role in shaping the tumor microenvironment. Elevated FAK signaling promotes recruitment of immunosuppressive cells — including regulatory T cells and myeloid-derived suppressor cells — and increases expression of immune checkpoint molecules like PD-L1. This immunosuppressive effect explains why some mesothelioma tumors resist immunotherapy and provides the scientific basis for combining FAK inhibitors with checkpoint inhibitors.

What Did the COMMAND Trial Reveal About Defactinib?

The COMMAND trial (NCT01870609) remains the largest randomized clinical trial of a FAK inhibitor in mesothelioma. Published in The Lancet Respiratory Medicine in 2018, this Phase II study tested defactinib as maintenance therapy in patients with malignant pleural mesothelioma who had achieved at least stable disease after four cycles of first-line platinum/pemetrexed chemotherapy.^[4]

The trial randomized 344 patients (2:1) to receive either defactinib 400 mg twice daily or placebo. The primary endpoint was progression-free survival (PFS). In the intention-to-treat population, defactinib did not improve PFS: median 4.1 months in the defactinib arm versus 4.0 months with placebo (HR 1.04, 95% CI 0.79-1.37, p=0.86).^[4] Overall survival was also not different between groups.

At first glance, the COMMAND trial appears to be a negative result. However, the pre-specified biomarker analysis told a different story. The trial prospectively collected tumor tissue and assessed merlin expression by immunohistochemistry (IHC). Patients classified as merlin-low experienced a meaningful benefit from defactinib, with a hazard ratio of 0.56 for progression-free survival — a 44% reduction in disease progression risk compared to placebo.

"The COMMAND trial is a textbook example of why biomarkers matter in oncology. The overall results looked negative, but buried in the data was a clear signal: merlin-low patients benefited significantly. That finding has reshaped how researchers think about FAK inhibitors in mesothelioma — it's not about treating everyone, it's about treating the right patients."

— David Foster, Executive Director of Client Services, Danziger & De Llano

Why Is Merlin/NF2 Status Critical for Predicting FAK Inhibitor Response?

The COMMAND trial's biomarker findings established a biological framework for understanding who benefits from FAK inhibition. Merlin (encoded by NF2) acts as a molecular brake on FAK activity. In tumors where merlin is intact, FAK activity is already partially restrained, and adding a FAK inhibitor provides little additional benefit. In merlin-deficient tumors, FAK is the primary driver of cell survival — removing that driver with defactinib creates a genuine therapeutic vulnerability.

NF2 loss is one of the most common genetic events in mesothelioma, occurring through gene deletion, mutation, or epigenetic silencing. Studies have documented NF2 inactivation in 40-50% of mesothelioma tumors, making this a substantial patient population. Importantly, NF2 loss is more frequent in nonepithelioid subtypes (sarcomatoid and biphasic), which tend to have worse prognosis and fewer effective treatment options — precisely the patients who need new therapies most.

Testing for merlin status can be performed using immunohistochemistry (IHC) on standard tumor biopsy tissue. While no FDA-approved companion diagnostic currently exists for merlin/FAK inhibitor selection, the COMMAND trial demonstrated that IHC-based merlin assessment is feasible in clinical practice. As referenced in the mesothelioma FAQ, patients should discuss molecular testing with their oncology team to understand their tumor's specific genetic profile.

How Could FAK Inhibitors Enhance Immunotherapy Response?

One of the most promising directions for FAK inhibitors is their potential to overcome resistance to immune checkpoint therapy. Research published in Nature Reviews Cancer and other peer-reviewed journals has demonstrated that FAK signaling actively promotes an immunosuppressive tumor microenvironment through multiple mechanisms.^[11]

Elevated FAK activity drives recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) into the tumor, creating an immune-privileged niche that shields cancer cells from immune attack. FAK also upregulates PD-L1 expression on tumor cells, directly suppressing T cell function. Preclinical models show that FAK inhibition reverses these immunosuppressive changes — reducing Treg and MDSC infiltration while increasing cytotoxic T cell access to the tumor.

This biology provides a strong rationale for combining FAK inhibitors with anti-PD-1 or anti-PD-L1 checkpoint inhibitors. The first-line mesothelioma immunotherapy regimen of nivolumab plus ipilimumab, approved by the FDA for mesothelioma, has shown meaningful clinical benefit in the CheckMate 743 trial. Adding a FAK inhibitor could potentially improve these results by making the tumor microenvironment more permissive to immune-mediated killing. As documented in the NCI's mesothelioma clinical trials database, several combination studies are exploring this approach.

"The idea of combining FAK inhibitors with immunotherapy is exciting because it attacks the problem from two angles. The FAK inhibitor strips away the tumor's immune shield, and the checkpoint inhibitor unleashes T cells to attack. For patients who haven't responded to immunotherapy alone, this combination could be the key to unlocking a response."

— David Foster, Executive Director of Client Services, Danziger & De Llano

What Combination Strategies Are Researchers Exploring?

The failure of defactinib as a single-agent maintenance therapy in unselected patients has redirected the FAK inhibitor field toward two main strategies: biomarker-selected monotherapy and rational combination therapy.

FAK + Immunotherapy: The most actively pursued combination pairs FAK inhibitors with immune checkpoint inhibitors. Preclinical data in mesothelioma models demonstrate synergy between FAK inhibition and anti-PD-1 therapy, with combination-treated animals showing superior tumor regression compared to either agent alone. Clinical trials testing this approach are emerging, and researchers at the NCI-designated cancer centers are leading enrollment efforts.

FAK + MEK Inhibitors: FAK and MEK (mitogen-activated protein kinase kinase) operate in interconnected signaling networks. In mesothelioma cells with NF2 loss, both FAK and RAS-MEK-ERK pathways may be co-activated. Dual inhibition has shown enhanced anti-tumor activity in preclinical models, particularly in sarcomatoid and biphasic subtypes.

Biomarker-Selected Trials: Future trials are expected to enroll only merlin-low patients, based on the COMMAND trial's biomarker signal. This enrichment strategy should increase the likelihood of demonstrating a statistically significant and clinically meaningful treatment effect — avoiding the dilution that occurred when all-comers were included in the original trial.

What Should Patients Who Have Exhausted Standard Options Know?

For mesothelioma patients whose disease has progressed after platinum-based chemotherapy and checkpoint immunotherapy, defactinib and FAK inhibitors represent one of several investigational approaches worth discussing with their treatment team. The key considerations include molecular testing, trial access, and financial planning.

Molecular testing: Patients should request comprehensive molecular profiling of their tumor, including NF2/merlin status. According to SEER data, only approximately 3,000 new mesothelioma cases are diagnosed annually in the United States, making each patient's molecular profile critical for matching to the right trial. Knowing whether your tumor is merlin-low can help determine whether a FAK inhibitor trial is appropriate.

Clinical trial access: Patients can search ClinicalTrials.gov for active FAK inhibitor studies and monitor the WikiMesothelioma clinical trials page for updates on emerging mesothelioma-specific studies. Major cancer centers including MD Anderson, Memorial Sloan Kettering, and Brigham and Women's Hospital typically have the broadest portfolios of mesothelioma trials.

Financial planning: Clinical trial participation often involves travel to specialized centers, lodging, and ancillary costs that insurance may not cover. Pursuing asbestos trust fund claims and exploring veterans benefits can provide financial resources to support treatment access. Our free case assessment helps determine what compensation pathways are available.

"When standard treatments stop working, patients need to know that the science hasn't given up on them. FAK inhibitors, TEAD inhibitors, CAR T-cell therapy — there are more investigational options for mesothelioma today than at any point in history. The key is getting molecular profiling done and connecting with a treatment center that has active trials."

— David Foster, Executive Director of Client Services, Danziger & De Llano

What Does FAK Inhibitor Research Mean for the Future of Mesothelioma Treatment?

The defactinib story illustrates a broader shift in mesothelioma drug development: away from one-size-fits-all approaches and toward precision medicine guided by tumor biomarkers. The COMMAND trial's overall negative result initially appeared to close the door on FAK inhibitors. Instead, the merlin biomarker finding has opened a more focused path — one that could ultimately prove more effective than the original unselected strategy.

This lesson extends beyond FAK inhibitors. Mesothelioma is increasingly understood as a molecularly heterogeneous disease, where NF2 loss, BAP1 mutations, CDKN2A deletions, and Hippo pathway alterations define distinct subtypes with different therapeutic vulnerabilities. The future of mesothelioma treatment likely involves matching each patient's tumor profile to the most effective targeted agent or combination, rather than applying the same therapy to all patients.

For patients and families navigating a mesothelioma diagnosis, the practical takeaway is clear: comprehensive molecular testing should be part of every treatment plan. Understanding your tumor's genetic drivers — including merlin/NF2 status — can open doors to clinical trials and investigational therapies that would otherwise remain invisible. Resources like the mesothelioma treatment options guide and the NCI's clinical trials database provide starting points for exploring what's available.

"I've spent two decades in this space, and I'm genuinely optimistic about where mesothelioma treatment is heading. The COMMAND trial taught us that biomarkers aren't optional — they're essential. Every patient deserves to know their tumor's molecular profile. That information is the bridge between a standard protocol and a precision therapy that could change your outcome."

— David Foster, Executive Director of Client Services, Danziger & De Llano

---

References

1. [1] WikiMesothelioma, "Clinical Trials" — Comprehensive guide to active mesothelioma clinical trials including FAK inhibitor and combination therapy studies.
2. [2] WikiMesothelioma, "Treatment Options" — Overview of mesothelioma treatment modalities including surgery, chemotherapy, immunotherapy, and emerging targeted therapies.
3. [3] WikiMesothelioma, "Mesothelioma FAQ" — Frequently asked questions about mesothelioma diagnosis, treatment, and molecular testing.
4. [4] ClinicalTrials.gov, "COMMAND Trial — Defactinib in Malignant Pleural Mesothelioma (NCT01870609)" (2018) — Phase II randomized, double-blind, placebo-controlled trial registry for defactinib maintenance therapy in 344 MPM patients.
5. [5] The Lancet Respiratory Medicine, "Defactinib versus placebo as maintenance therapy in malignant pleural mesothelioma: the COMMAND trial" (2018) — Peer-reviewed publication of COMMAND trial results demonstrating merlin-low biomarker signal (HR 0.56).
6. [6] National Cancer Institute, "Clinical Trials for Mesothelioma" (2025) — Federal database of mesothelioma clinical trials including targeted therapy and combination immunotherapy studies.
7. [7] National Cancer Institute, "Mesothelioma Treatment (PDQ) — Patient Version" (2025) — Comprehensive NCI guide to mesothelioma treatment options, staging, and clinical trial access.
8. [8] U.S. Food and Drug Administration, "Oncology Approval Notifications" (2026) — FDA database of approved oncology drugs including checkpoint inhibitors approved for mesothelioma.
9. [9] SEER / National Cancer Institute, "Cancer Statistics Explorer — Mesothelioma" (2025) — Surveillance, Epidemiology, and End Results data on mesothelioma incidence, survival, and demographics.
10. [10] British Journal of Cancer, "FAK signalling controls cell survival and chemoresistance in cancer" (2018) — Peer-reviewed analysis of FAK signaling in cancer cell survival, immunosuppression, and therapeutic resistance.
11. [11] Nature Reviews Cancer, "FAK as a therapeutic target in cancer" (2014) — Comprehensive review of FAK biology, clinical development of FAK inhibitors, and biomarker strategies for patient selection.
12. [12] Journal of Thoracic Oncology, "NF2/Merlin inactivation and FAK activation in mesothelioma" (2017) — Research establishing the mechanistic link between NF2 loss, merlin deficiency, and constitutive FAK activation in pleural mesothelioma.